Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity

NCT05311215 is registered in ClinicalTrials.gov with Saol Therapeutics Inc as lead sponsor.

NCT NCT05311215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05311215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Single Ascending Dose Escalation Study to Assess the Safety, Pharmacokinetics and Efficacy of SL-1002 in Patients With Limb Spasticity
Lead sponsor
Saol Therapeutics Inc
Phase
Phase 2
Overall status
Unknown status
Start date
April 22, 2022
Completion date
September 30, 2023
Enrollment
32 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

spasticity